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An increasing number of U.S.
hospitals are saving money by
reusing medical devices originally approved for only onetime use, thereby ignoring the
warnings posted by the manufacturers of such devices.
The Food and Drug Administration defines a medical
device as “any health care
product that does not achieve
its primary intended purpose
by chemical action or by being
metabolized.”
Some medical devices are
classified as single-use devices
(SUDs). SUDs are considered
by the manufacturer to only

be safe for a one-time use and
must be discarded after being
used. However, hospitals have
implemented procedures to
reprocess some of these
SUDs.
Examples of SUDs that are
currently being reprocessed
include surgical drills, biopsy
forceps, electrophysiology
catheters, cartilage knives,
trocars, and laparoscopy scissors.

Types of Medical Devices
x

Sutures

x

Pacemakers

x

Vascular grafts

x

Intraocular lenses

x

Orthopedic pins

x

Test kits for in-vitro
diagnoses for disease

x

Test kits for pregnancy

Hospitals are not required to
inform patients that they may
receive a device that the hospital has chosen to reuse
against the manufacturer’s
recommendation. Currently,
three out of four surgeons
believe that reprocessing
See “Savings” on Page 9

Mental Health Parity
The Next Step in the
Mental Health
Revolution
By Shelly Weizman
weizmash@shu.edu

The concept of “mental
health parity” refers to a requirement that health benefits
companies, including managed care and insurance com-

panies, provide the same insurance coverage for mental
health treatment that they
provide for other medical
treatments.
Under most health benefits
plans, there is a dramatic disparity in coverage between
mental and physical health
services. The goal of the men-

tal health parity initiative is to
eliminate this disparity
through legislation that mandates equal coverage for all
health services. While opponents of parity argue cost as a
reason for denial of coverage,
proponents of an equal system argue that the practice of
See “Parity” on Page 6
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New Patent Application Practices
The Controversy Over
Proposed Limits
By Sarah Geers
geerssar@shu.edu

The pharmaceutical industry, comprised of both “innovator” and
“generic” drug companies, plays a
significant role in the American health
care system. However, the dazzling
scientific achievements that enable the
development of new drugs are only
possible when sandwiched between
two cornerstones of the system: the
public health safeguards of the FDA’s
regulatory process and the economic
safeguards of the United States patent
system.

cations and granting patents, as well as
creating the rules that govern this
process. Recently, the USPTO issued
final administrative rule changes that
“THE

EXPECTED

IMPACT OF THESE
CHANGES IS
EXPANSIVE, AS
CHARACTERIZED BY
STRONG
OBJECTIONS FROM
MAJOR
PHARMACEUTICAL
COMPANIES”

significantly altered these patent
prosecution procedures, which were
set to take effect on November 1,
2007. The most significant rule
changes target the number of claims
allowed in each patent application and
the number of subsequent related
applications allowed. The implementation of these new rules is expected
to significantly alter this economic
balance between research-based and
generic drug companies.

A strong patent system provides incentives to innovator drug companies
to invest in the risky, lengthy, and
expensive drug discovery process,
while the later expiration of the patents (combined with FDA review and
approval) allows generic drug companies to benefit from the discovery and
clinical foundation laid by the innovators. The American public ultimately
benefits from the tension between
innovation and commoditization that
our patent system encourages.

Representing the “Big Pharma” perspective in the debate is GlaxoSmithKline (GSK), which has vigorously
opposed the rule changes by filing suit
against the USPTO in federal court to
enjoin the implementation of the new
requirements. The USPTO continues
to defend the rule changes (and presumably generic company interests)
while GSK aggressively defends the
status quo. A comparison of historical
practices and the proposed revisions
highlights what is at stake for these
parties.

The Debate: The USPTO vs. GSK
and “Big Pharma”

The New Claims and Applications
Requirements

In this system, the United States Patent and Trademark Office (USPTO) is
responsible for reviewing patent appli-

A “claim” is the portion of the patent
that specifically describes the claimed
invention, in essence carving out the

exact invention space to which the
applicant claims exclusivity. While a
patent application may discuss a broad
or far-reaching innovation, the inventor is required to specify the exact
scope of the protection he or she
seeks, usually in the form of a list of
discrete sub-units of all possible variations of the invention conceived. The
previous USPTO practice allowed an
unlimited number of claims in the
application, but the proposed rules
will cap applicant claims at twenty-five
(five independent claims, and twenty
dependent claims, i.e., claims that are
smaller sub-sets of and hence
“dependent” on the independent
claims for their focus).
The current USPTO patent application practice also has a number of
ways in which an applicant may continue the subject matter of the original
application in further applications.
These continuing applications may be
filed for strategic (portfolioenhancing) reasons or due to difficulties expected or encountered in the
application process. Previously, continuing applications were not limited,
but the new rules impose a cap of two
continuing applications and one request for continuing examination.
Expected Impact of Changes in the
Health Law Field
The expected impact of these changes
on the health law field is expansive, as
characterized by the strong objections
from major brand-name pharmaceutical companies, led by GSK. In its
ongoing suit against the USPTO, GSK
alleges that the new rules extend beyond its rulemaking authority, effecting a substantive rather than procedural rule change. Apart from questioning the legality of the rule changes,
GSK also attacks the changes as being
See “Patent Practices” on Page 10
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‘Meta-Care’ and ‘Meta-Caid’
Changing How the
Government Prices Drugs
Recent changes in the way the federal
healthcare programs of Medicare and
Medicaid price prescription drugs impact everyone who makes, consumes,
sells, or prescribes prescription drugs.

mechanisms and payment formulas
for prescription drugs. These shifts in
the drug pricing system are expected
to save the government billions of
dollars over the next several years by
lowering healthcare costs; however,
the shifts will also create a ripple effect
which drastically changes the future of
the healthcare industry.

In order to alleviate concerns that
Medicare and Medicaid have been
overpaying for drugs due to inaccurate
pricing by drug companies, the federal
government established new pricing

Before the new pricing systems were
implemented, Medicare and Medicaid
paid for drugs based on the “average
wholesale price” (AWP) of the prescription drug, minus five percent of

By Marc Adler
adlermar@shu.edu

the cost of the drug. AWP was intended to represent the average price
at which wholesalers (who purchase
drugs from manufacturers) sell drugs
to physicians, pharmacies and other
customers.
The AWP of a drug was commonly
referred to as “Ain’t What’s Paid,”
because it was not an accurate reflection of the market price of a drug
Rather, AWP more closely resembled
a “list price” or “sticker price” because
it is established from self-reported
See “Meta-Care” on Page 8

The ACCESS Act and Its Effect on the FDA Mission

Earlier Access to
Experimental Drugs
By Nicole Ho
honicole@shu.edu

On November 3, 2005, Senator Sam
Brownback (R-KS) introduced the
Access, Compassion, Care and Ethics
for Seriously-Ill Patients Bill (ACCESS
Act) in the Senate (S. 1956). The Act
proposes a new approval process for
experimental drugs, allowing earlier
access for seriously-ill patients who
have exhausted other treatment options.
Under this bill experimental drugs
would be available to patients after
completion of Phase I clinical trials.
Additionally, the bill would remove
the placebo arm from all clinical trial
designs. The proposed ACCESS Act

is controversial among patient groups,
healthcare workers, pharmaceutical
companies, and government agencies.
The FDA claims that widespread access to unapproved drugs may disturb
the balance of risks and benefits protected by the current approval system.
Phase I studies are performed on a
small patient population with the primary purpose of determining maximum safety limits.
Phase II studies test the experimental
drug’s efficacy within a larger patient
population, often revealing severe
adverse reactions that Phase I studies
did not expose.
Phase III studies determine the statistical significance of drug efficacy by
further expansion of patient populations using the most effective dose
determined in Phase II studies.
Opponents of the ACCESS Act
The FDA claims that allowing patients
access to experimental drugs after
Phase I studies not only poses great
safety concerns, but may also give
patients a false hope of a cure. Simi-

larly, the United States Society for
Clinical Trials opposes the ACCESS
Act, claiming the Act undermines scientifically valid testing of new drugs.
Although the proposed law provides
more treatment choices, patients and
their physicians are less informed regarding safety and effectiveness of
these drugs. Patients may receive less
effective treatments or may be subject
to severe or unforeseen adverse effects. Clinical trials designed to determine efficacy depend on placebo arms
for accurate analysis. Early access
without the use of placebos threatens
any evidence of efficacy drug trials
would attempt to prove.
Proponents of the ACCESS Act
Supporters of the ACCESS Act believe there are serious concerns about
the FDA’s drug approval process,
especially the speed of drug approval.
Currently, patients may receive experimental drugs before market approval
through the FDA’s “compassionate
use” program. This program grants
seriously ill patients access to
See “ACCESS Act” on Page 7
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Rationalizing Health Care Resources in New Jersey
The New Jersey Commission
on Rationalizing Health Care
Resources Releases its Final
Report

By Kathleen M. Boozang, Professor of Law, Seton Hall Law School
On January 24, 2008, the New Jersey
Commission on Rationalizing Health Care
Resources, created by Governor Jon
Corzine fifteen months earlier, and
chaired by internationally renowned
health economist Uwe E. Reinhardt,
Ph.D., released its final Report on
New Jersey’s ailing healthcare system,
focusing particularly on the state’s
financially distressed hospitals.
The Report comes as Governor Corzine attempts to negotiate the state
through a variety of unappealing options to reduce its $32 billion debt.
New Jersey’s current $3 billion budget
short-fall is the third highest in the
nation, following New York and California. Given this state of financial
affairs and the fact that unlike a similar
commission in New York, the New
Jersey Commission was created by
executive order rather than statute, no
one expects quick fixes. Consequently,
the Commission’s recommendations
are just that, and therefore require
legislative enactment, regulatory adoption, or voluntary implementation to
take effect.
The Commission’s Findings
The New Jersey Commission did not
target specific hospitals for closure,
instead developing a framework for
identifying which financially distressed
hospitals should receive state support.
The past fifteen years have seen
twenty-one hospital closures in New
Jersey; there have been five hospital
bankruptcies in New Jersey since July
2006. All expectations are that more
closures will come – over half of the
state’s remaining seventy-nine acute
care hospitals are losing money. In
2008, two urban hospitals in North
Jersey, where the most seriously distressed hospitals are located, have

already notified the state of their closure plans. Low margins and low cash
on hand represent only a part of the
landscape of New Jersey’s distressed
hospitals. A median long-term debt to
capitalization ratio of 52.5% precludes
hospitals from investing in infrastructure, which has resulted in a very high
average age of plant and limited investment in IT infrastructure.

Ultimately, the Report attributes hospitals’ financial state to a number of
factors, with a primary focus on the
economic system in which hospitals
operate. Specifically, the inability of
hospitals to exercise control over physicians’ use of resources, gross underpayment by public payers, the overall
pricing system employed by the industry (as among hospitals as well as between hospitals and ambulatory centers) and insurers, and, in some cases,
poor governance by hospital boards.
Ambulatory care facilities also present
competitive challenges to hospitals,
which are exacerbated by the less onerous regulatory environment in which
ambulatory surgical centers in particular operate.
The Commission’s
Recommendations

Most of the Commission’s findings
were of little surprise to close observers of the New Jersey healthcare market, including that hospital services are
utilized at a very high rate, typified by
the fact that chronically ill Medicare
beneficiaries see more physicians in a
year than those in any other state in
the nation. While New Jersey is overbedded, the surplus is not as dramatic
as that of other states and therefore
does not explain the extraordinary
excess in services or the hospitals’
uniquely challenging financial woes.
Neither can the state’s financial challenges be attributed to differences in
New Jersey’s population — according
to the Report, “New Jersey residents
are not poorer, older or more heavily
uninsured than the rest of the nation.”
Nonetheless, the state’s one million
uninsured, as well as its vulnerable
populations, encounter deficiencies in
extant primary and specialty care, especially treatment for mental health
and substance abuse.

As would be expected, how to strategically respond to the plight of financially distressed hospitals became the
major focus of the Commission’s recommendations to Governor Corzine.
The Report concludes that insolvent
non-essential hospitals should be allowed to close, albeit with procedures
to protect the employees and community.
To implement its recommendation
that the State should provide financial
support to “hospitals that are more
essential and less financially viable,”
the Commission proposes a formula
to balance metrics of a hospital’s
“essentiality” against metrics of its
financial viability. In developing this
approach, the New Jersey Commission borrowed in some respects from
the tact employed by the New York
Commission on Health Care Facilities in the
21st Century. As such, the New Jersey
Commission adopted three criteria for
analyzing a hospital’s essentiality: 1)
care for financially vulnerable populations; 2) provision of essential services
and 3) utilization. The criteria for financial viability
See “Rationalizing” on Page 5
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include profitability asmeasured by
operating margin, liquidity as measured by cash on hand, and capital
structure as measured by long-term
debt to capitalization. The Report
also enumerates several nonquantitative factors to be considered
in assessing State support, including,
inter alia, alternative sources of services
for the community, whether the hospital is part of a system that can provide additional resources, quality of
care and efficiency, and impact on
employment in the area.
A hospital’s receipt of state support
through a “Distressed Hospital Program” should be accompanied by
monitoring of efficiency, quality, and
overall financial health, according to
the Report. Apparently, the monitoring would occur in part through the
provision of a seat on the hospital’s
board to a state appointee. The Report also recommends that the Department of Health and Senior Services institute an Early Warning System for hospitals with evidence of
financial distress while there is still
time remaining to implement a turnaround plan. If closure nonetheless
results, the Report anticipates state
financial support to cover closing
costs.
The remainder of the Commission’s
recommendations follows several
broad themes. Transparency dominates proposed new regulation of ambulatory centers, hospitals and physicians, with a focus on access to information related to quality, pricing, conflicts of interest, and institutional governance and financial health. As conceived by the Commission, the public
would have access to quality data
ranging from physician report cards to
hospitals’ infection rates, sentinel
events and quality outcomes. Hospitals’ governance documents, 990s
(annual reporting forms that taxexempt hospitals must file with the
IRS), board composition and meeting
minutes would be available to the pub-

lic on the entities’ web pages. Patients
would have access to ambulatory centers’ charge masters as well as hospitals’ general pricing scheme and its fee
schedule and collection practices for
the uninsured. The Commission also
recognized the necessity of access to
data to improve efficiencies in the
acute care setting. As such, it recommends that the state collaborate with
industry to acquire and adapt software
to be employed throughout the state
to enable hospitals to track, and report
to both physicians and the state, the
average cost of care for each in-patient
of every physician.

The Commission also focused on recommendations to facilitate identification and management of a wide range
of conflicts of interest. At least one
set of conflicts, such as an attorney
serving in the dual capacities of counsel and director, is sought to be
banned. The Commission recommends managing others, by, for example, recommending that physicians be
required to disclose certain investment
interests to patients, and that hospital
boards receive information about
charitable contributions from vendors
and contractors.
Quality of governance received significant attention from the Commission,

with resultant recommendations focusing on the process by which boards
are comprised, a requirement of board
training (which had previously become
law in New Jersey), and a push for
transparency between management
and the board.
Acknowledging that many hospitals
have incorporated relevant portions of
Sarbanes-Oxley into their corporate
policies, the Commission also observed that a fair number of boards
have been static in both their composition and practices for many years,
contributing to their hospitals’ inability
to respond to the dynamism of the
market and the challenges of the industry.
The Commission Report takes two
approaches to improve governance:
best practices and regulation. Recommended regulations seek to require
boards to advertise open positions,
with an eye towards soliciting directors
with particular expertise or who cover
unrepresented constituencies, e.g., the
community or employees. Proposed
regulations would also require the
existence of audit and compensation
committees with clear powers that
closely resemble practices in the forprofit sector, as well as creation of
document destruction and retention
and conflict of interest policies. Suggested best practices include requiring
directors to participate in orientation
and training, ensuring that directors
receive the entity’s organic corporate
documents as well as its most recent
annual reports and financial statements, 990’s, and information about
leadership at the corporate and hospital level, and involving the board in
approving management’s selection of
legal counsel.
In several areas, the Report recommends further state commission studies tp produce approaches to improving health care delivery practices in the
state. So, for example, the Commission recommends retention of
See “Rationalizing” on Page 12
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denying coverage for necessary mental
health care must end.

illness are not receiving mental health
services.

Mental Health Disparity

x

Higher co-pays

x

Limits on the number of
outpatient visits

One major reason for the lack of treatment is inadequate and discriminatory
insurance coverage of mental health
services. In fact, eighty-seven percent
of health plans place limits on mental
health coverage that they do not place
on medical or surgical care. Consequently, most people — even people
who have coverage for mental health
conditions — find it much more expensive to receive treatment for mental illness than to receive treatment for
other illnesses or injuries.

Limits on the number of
inpatient hospital days covered

Inadequacy of Current State and
Federal Legislation

Lower quality measures

Most states have laws requiring some
form of parity in coverage; however,
these laws cannot comprehensively
mandate parity due to restrictions
found in the Employee Retirement
Income Security Act (ERISA). Under

In any given year, twenty-six percent
of adults and over twenty percent of
children have or will have a diagnosable mental or addictive disorder.

Common Disparities in
Mental Health Coverage:

x
x

Despite these statistics, only forty-one
percent of people with a mental illness
receive treatment and almost four out
of five children who have a mental
Provisions
Prohibitions or
Requirements

House Bill (H.R. 1424)

ERISA, employees that are the beneficiaries of “self-insured” health benefits
plans are categorically excluded from
state parity laws. Under such plans,
the employer becomes the provider of
“TWENTY-SIX
PERCENT OF
ADULTS AND OVER
TWENTY PERCENT
OF CHILDREN HAVE
A MENTAL OR
ADDICTIVE
DISORDER”

health benefits and takes the primary
risk of providing benefits.
All large multi-state employers and
many medium single-state employers
now self-insure. Only the national
government has the authority to regulSee “Parity” on Page 7
Senate Bill (S. 558)

Prohibits treatment limitations or financial re- Requires plans to provide financial requirequirements not similarly imposed on other medi- ments and treatment limitations that are no
cal benefits (same co-pays, deductibles, etc.)
more restrictive than those of all the other
benefits (same co-pays, deductibles, etc.)

Minimum Benefit
Requirement

Same mental health coverage that is offered to No minimum benefit requirement
federal employees

Definition of
“Mental Illness”

All conditions listed in the Diagnostic and Statis- Health plans may define if no definition is
tical Manual (DSM-IV)
advanced by the state

Self-Insured Coverage Covers self-insured plans

Covers self-insured plans

Preemption Provision Explicitly protects stronger state parity laws

No preemption provision

Mental Health
Coverage Mandate

No mandate - only covers plans that provide any No mandate - only covers plans that provide
mental health coverage at all
any mental health coverage at all

Small Employer
Exemption

Excludes employers with 50 employees or less

Cost Exemption

Exempts plans whose costs of compliance in- Exempts plans whose costs of compliance
creases total costs of coverage by 2%
increases total costs of coverage by 2%

Status of Bill as of 3/25/08 Passed House on March 5, 2008
Original Chart by Shelly Weizman

Excludes employers with 50 employees or
less

Passed Senate on September 18, 2007
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ate these plans. Since about half of
the people who have health benefits
through their employers are covered
by self-insured plans, only half the
people with health insurance actually
benefit from state parity laws. As
such, a comprehensive federal parity
law is the only effective method of
reaching employees in these plans and
mandating far-reaching coverage of
mental health services in all health
benefits plans.
While one federal parity law, the Mental Health Parity Act of 1996, currently
exists, the law inadequately addresses
disparities in mental health coverage
because qualified health plans are only
required to provide parity with regard

to limits on covered annual and lifetime costs.
A Federal Law – The
Comprehensive Solution

Only

Due to the limited reach of current
federal and state laws, two federal
parity bills were introduced in Congress in 2007, one in the House and
the other in the Senate.
Many mental health advocates favor
the House bill, which is clearly the
more extensive of the two. The Senate bill, lauded as a compromise between mental health advocates and the
business community, contains numerous restrictions and raises multiple
concerns among some proponents.

Both bills have passed their respective
houses and negotiations to construct a
mental health parity bill acceptable to
both chambers of Congress will likely
resume in the next Congressional session, which begins in 2009. One of the
main areas to be agreed upon is the
minimum benefit standard.
This nation has made huge strides in
the areas of mental health rights over
the past several decades, but there is
still much more that needs to be accomplished. Disparity in coverage is
unconscionable in a country with such
rich and vast health care resources.
The passage of federal mental health
parity legislation is the next logical
step forward on the road to reform.
See Pages 12-13 for Citations
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unapproved drugs after completion of
Phase II clinical trials. However, latestage cancer patients may die while
waiting for compassionate use approval by the FDA. Supporters of the
Act also oppose the current clinical
trial design mandated by the FDA.
Patients are often excluded from clinical trials because of the strict admission requirements. Even if patients
succeed in being admitted into a clinical trial, they may receive a placebo
rather than the active drug. Many supporters of the ACCESS Act find this
practice unethical.
The Abigail Alliance for Better Access
to Experimental Drugs (Abigail Alliance), a patient advocate group, fully
supports Senator Brownback’s ACCESS Act. The Abigail Alliance argues
that decisions to use experimental
drugs should be between a patient and
his/her physician. The Abigail Alliance emerged when the FDA denied
Abigail Burroughs access to unap-

proved cancer drugs. The FDA eventually approved Erbitux for the same
type of cancer that killed Abigail. At
the time of Abigail’s request, however,
Phase II studies, designed to determine efficacious dosing, had not been
completed. The FDA was concerned
that if Abigail had been given Erbitux,
her physician would have run the risk
of administering too high or too low a
dose, with no guarantee of recovery.
The Abigail Alliance sued the FDA,
claiming that denial of experimental
drugs violates a patient’s constitutional
right. On appeal, the D.C. Circuit
held, eight to two, that there is no
fundamental right grounded in the
Constitution to grant access to investigational drugs. The United States Supreme Court subsequently denied
certiorari on this case.
Looking Forward
The solution to this controversy may
be a middle-ground compromise. The
FDA has addressed some of these

concerns by proposing to amend its
regulations on access to experimental
drugs. The proposed regulations grant
access to unapproved drugs during
emergencies and for increased number
of patients to be allowed in each trial.
However, patients would still be required to exhaust all other treatment
options.
This proposal attempts to balance the
benefits of expanded access with the
risks involved in pre-Phase II access.
At the core of this issue is the question of how the FDA can save thousands of people suffering from terminal illnesses. The only way to ensure
the successful approval of safe and
effective drugs is to perform properlycontrolled clinical trials. The ACCESS
Act’s passage will defeat the FDA’s
mission of approving safe and effective drugs, something that the FDA
has been working towards for over
100 years.
See Page 13 for Citations
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manufacturer data that was not truly
defined by any laws or regulations.
Therefore, drug manufacturers were
free to set the AWP at any level, regardless of the actual market prices
paid by physicians and suppliers who
pay for the products.
In response to reports of fraudulent
activity and the abuse of Medicare
reimbursement under the old AWP
system, the government adopted two
new pricing systems — one for Medicare Part B (which covers physician
visits) and one for all prescription
drugs under Medicaid.
The average sales price (ASP) drug
pricing system, which was adopted
along with the Medicare Prescription
Drug, Improvement and Modernization Act of 2003, applies to Medicare
Part B covered drugs and biologics
(referred to collectively as “drugs”).
These drugs are not usually purchased
at retail pharmacies; rather, healthcare
providers — such as physicians —
buy these drugs and then bill Medicare
after they administer the drugs to patients.
The second new pricing system is the
revised average manufacturer price
(AMP) system. Unlike the ASP system, the revised AMP rule applies to
all drugs which may be sold in the
United States at retail pharmacies.
Another important distinction between ASP and AMP is that AMP
applies to the reimbursement for
drugs under Medicaid, and not Medicare Part B.
AMP System

ASP System

Applies to all
drugs purchased at retail
pharmacies
under Medicaid

Applies to drugs
covered under
Medicare Part B

Despite the fact that the ASP and
AMP systems are quite different, both
systems reflect the government’s desire to create more accurate drug
prices and reduce overpayments made
by its healthcare programs.
It is important to remember, however,
that these pricing mechanisms only
apply to government reimbursement
under Medicare Part B or Medicaid
and not to the reimbursement for
private payers such as health plans.
Nevertheless, the shifts in reimbursement are significant because of the
effect that these pricing methodologies may have on private payers in the
near future. In fact, a recent survey
shows that in 2007, approximately half
of the health plans surveyed intended
to use the ASP system for pricing the
same drugs which are covered under
Medicare Part B. Similarly, the AMP
system is likely to have a more expansive effect since private payers will
likely adopt AMP as a more reliable
and inexpensive pricing benchmark
for all other drugs.
Therefore, given the potential impact
of the ASP and revised AMP drug
reimbursement systems, three questions need to be addressed in order to
evaluate the suitability of these monumental shifts in drug pricing. First,
will these shifts appropriately reduce the
waste, fraud and abuse concerns that
plagued Medicare and Medicaid in the
past? Second, how will these shifts
affect access to quality care? Finally,
which solutions should be considered
and/or implemented in order to ensure consistency and fairness with
respect to drug pricing and reimbursement?
In response to the question of
whether the switch to new drug reimbursement systems is justified, the
answer appears to be “yes.” Under
Medicare Part B, the ASP system appropriately reduced the waste, fraud
and abuse concerns that occurred in
the program under the old AWP system. For example, drug prices are

now less likely to be inflated because
they are based on actual sales data
which is regularly reported to the government. This is in contrast to the less
transparent AWP system where the
prices were self-determined by drug
manufacturers in a more closed process using data that was not defined by
law or regulation. Moreover, the ASP
system decreased Medicare overpayments through a reduction of the
“spread” offered to physicians by including most price concessions in the
sales data.

The change to the ASP system has not
only reduced waste, fraud and abuse
concerns, but it has also allowed continued access to quality care received
by Medicare beneficiaries with respect
to physician-administered drugs and
services. Although many feared that
the ASP system would force physicians to stop administering drugs due
to lower reimbursement rates, physicians have adjusted their practice patterns and, in general, continue to enjoy
profitability. In order to ensure profitability in the future, however, the government must continue to monitor
and work with physician practices in
regard to various aspects of their business, such as negotiating lower drug
prices.
Similarly, the AMP system under
Medicaid has responded to the waste,
fraud and abuse concerns that the
program was overpaying for drugs by
relying on published prices that did
See “Meta-Care” on Page 11

VOLUME 1, ISSUE 1

Savings,

PAGE 9

Continued...

devices poses a health risk to patients
and seventy-four percent of surgeons
strongly believe that medical devices
should not be reprocessed. Hospitals
claim that reusing devices saves a substantial amount of money and that
there is no risk of harm because the
devices are sterilized and are held to
the highest standards.
Ramifications of Medical Device
Reuse
Medical device reuse has become a
much more serious issue than has
been recognized in the past. In the
United States, there are several documented cases with one major similarity: the injured patient had a reused
medical device implanted or used on
him or her during a procedure.
“SEVENTYFOUR PERCENT
OF SURGEONS
STRONGLY
BELIEVE THAT
DEVICES
SHOULD NOT BE
REPROCESSED.”

One glaring case that shows the potential danger of reusing medical devices involved patients who had undergone brain surgeries. A rarely seen
medical condition known as
Creutzfeldt-Jakob disease (CJD),
which causes the deterioration of normal brain functions and eventually
leads to death, was being seen more
frequently in certain hospitals. The
apparent cause of the increase in the
number of cases was the fact that a
surgical device used to relieve cranial
pressure for one patient with CJD had
been reused multiple times. As a result, numerous patients became infected or had the possibility of later

contracting this deadly disease.
Peripheral problems associated with
reused medical devices have also increased in recent years. One example
is the growth of poorly regulated reprocessing companies. Originally, hospitals would reprocess medical devices
in-house. Due to the FDA’s revised
reprocessed device regulations,
amended in 2000, hospitals have begun contracting third-party reprocessing companies to perform the service.
In 2006, the reprocessing market was
valued at $130 million. Growth experts project that by 2010 the market
will be valued at over $200 million.
Although hospitals claim that reusing
devices saves tens of millions of dollars a year, the Association of Device
Manufacturers claims that “single use
devices typically contain difficult-toaccess areas that create barriers to
cleaning and permit blood, tissue, or
other bodily fluids to contaminate the
reprocessed device, allowing potential
transmission of viral and bacterial
infections.”
To date, the FDA has no set number
of inspectors assigned to reprocessing
facilities. Rather, the agency relies on
doctors to voluntarily report problems
with faulty medical devices, and facilities are required to report deaths to
the FDA, but not device malfunctions.
Efforts to Reduce Medical Device
Reuse at the Federal Level
A number of measures have been
taken which have helped minimize the
number of devices that are reprocessed. The Medical Device User Fee
Act (MDUFA), which Congress recently passed, requires the federal government to study and report the number of infections attributable to new or
reused medical devices. This study will
also examine the possible causes of
these infections.

Areas of Study Required Under
MDUFA
x

Whether infections were acquired
from reprocessed SUDs

x

Handling of medical devices

x

In-hospital sterilization of medical
devices

x

Healthcare professional practices
for patient examination and treatment

x

Hospital-based policies for infection control and prevention

x

Hospital-based practices for handling medical waste

In addition, the FDA now requires
that all reprocessed SUDs entering
into interstate commerce must
“prominently and conspicuously” bear
the statement: “Reprocessed Device
for Single Use. Reprocessed By [name
of manufacturer that reprocessed the
device].” Another recent piece of legislation, the Healthy Hospitals Act,
requires hospitals to publicly report
their infection rates. The reporting
gives patients an informed choice
when selecting hospitals for care. This
Act also provides funding to the hospital from the savings by reducing
infection rates to zero.
“TO CATCH THE READER' S ATTENTION, PLACE AN INTERESTING SENTENCE OR QUOTE FROM THE STORY HERE.”

States Taking Action
Currently, Massachusetts has a law
that requires hospitals to obtain a patient’s informed consent regarding the
implanting of a reused medical device.
Re-processors are saying that they
would support such legislation nationwide as long as hospitals are also required to disclose the risks of new
devices, thereby exposing all risks for
See “Savings” on Page 11
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detrimental to health care innovation:
“The scientific research and discovery
of a new drug and the following clinical development takes a decade or
more of hard work and often a billion
dollars in completely at-risk investment.”

entability of an invention could cause
future drug abandonment if return on
investment was unlikely. Essentially,
GSK seems to argue that maintaining
the status quo is the best way to avoid
upsetting practices that favor innovation.

The company (and presumably others
like it) simply “cannot afford to undertake the huge investment” that is required to develop drugs without
strong patent protection. GSK even
cites one estimate that investment in
innovation “may ‘decrease by approximately [sixty percent]’ without adequate patent protection.”

Potential Benefits of the New
Rules

With respect to continuation practice,
GSK routinely returns to its initial
patent application to select a new lead
drug candidate after a first candidate
fails in testing. Under the new rules,
filing a related follow-on patent to
protect this new selection would not
be permitted (despite the fact that the
continuing application does not increase the period of market exclusivity). Without strong patent protection
on the drug molecule, GSK would
have little incentive to develop the
second new molecule. This practice
pervades the industry; from 19961998, only 7.8% of patents filed were
pharmaceutical, while the industry
accounted for twenty-two percent of
continuation applications.
With respect to claim limitations, independent research has shown that
thirty-five percent of “important patents” (involved in patent litigation) in
all fields since 2002 contain more than
twenty-five claims. Although GSK
does not thoroughly address this issue,
the same concept of creating incentive
to innovate via strong (and perhaps
broad and flexible) patent protection
would presumably apply to claim limitations; any limitation on the pat-

Despite the claims of GSK and other
large pharmaceutical companies of the
potential to stifle innovation and discourage investment, the new rules may
actually prove to be advantageous to
overall healthcare. First, with potentially weaker patent protection, generic
drug companies could produce a generic version of drugs earlier, thus
making medicines more readily available to the public. However, this argument clearly assumes that innovators
continue to do the “heavy lifting” of
new drug discovery and development
with less incentive.

security of a granted patent at an earlier stage of drug development. Finally, a different type of innovation
may emerge. The potentially greater
freedom to explore the discoveries of
others because of reduced exclusivity
could actually increase the speed of
innovation, by putting the less desirable pieces of the “next best thing”
into the hands of a great number of
separate innovators, decreasing the
cycle time. Several businesses in the
copyright sector already proactively
embrace this concept through the
“Creative Commons” movement,
which eschews complete and exclusive
copyright protection in favor of allowing free selective uses. This movement seeks to offer a “best-of-bothworlds way to protect” works, encouraging certain uses and declaring other
rights reserved.
Perhaps the pharmaceutical industry
will follow suit as a consequence of
the new patent limitations imposed on
it. Clearly, the new rules may affect
the industry in any number of ways,
not all of which lead to the death of
innovator drugs.
Current Status

Second, pharmaceutical companies
could potentially maintain a similar
amount of protection by modifying
their patent prosecution strategies.
The enormous market for innovator
drugs should continue to provide an
incentive for finding a workable solution. Third, the USPTO claims that
the rule changes are designed to make
patent prosecution more efficient and
reliable. If true, this would undoubtedly be a benefit to the pharmaceutical
industry, which would receive the

As a result of this controversy surrounding the rule changes, particularly
the pharmaceutical industry outrage as
expressed by GSK, implementation
has been put on hold. On October
31, 2007, the U.S. District Court for
the Eastern District of Virginia
granted the preliminary injunction
filed by GSK in Tafas v. Dudas. With
many patent practitioners waiting anxiously for a final decision, only time
will tell if traditional discovery practices will continue to dominate or if
the rule changes will require a new
model, to the benefit or detriment of
the American health care system.
See Page 13 for Citations
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both new and reused devices.
Recommendations
Along with obtaining patient consent,
there are several solutions to alleviate
some of the major problems associated with medical device reuse. First,
the FDA should enhance the system
created to determine the amount of
infections from reused SUDs and
eliminate reuse in medical devices with
an unusually high infection rate. Second, health care providers need to
begin to work with medical device
companies to inform patients of

whether or not they are obtaining a
reused medical device.
Patients have the right to know
whether a SUD has already been implanted or used on another patient
before the device is used on them.

Finally, for a modest fee, patients
should be able to request a new device
for implantation. Otherwise, patients
are subject to the possibility of being
exposed to an unnecessary risk of
hospital-acquired infections and medical device failures.
Medical device reuse is a national issue
of concern that must be addressed.
Through the help of the FDA and
other government agencies, this problem is slowly but surely coming to the
forefront of our nation’s healthcare
issues and will hopefully be resolved.
See Page 12 for citations
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the public for use by the states as the
basis for setting drug reimbursement.

not accurately reflect pharmacy acquisition costs. The government has
implemented several policies which
attempt to ensure that drug prices
more accurately reflect the cost for
pharmacies to acquire the drugs. For
instance, the revised AMP definition
helps drug manufacturers decipher
which type of sales the companies
should include in their AMP determinations, thereby lowering reimbursement rates. In addition, the new reporting requirements promote transparency within the drug pricing system. These reports show how manufacturers determine the price of their
drugs and make that data available to

Other government responses, however, may be less successful. For instance, the formula and calculation of
the “Federal Upper Limit” may significantly harm the profitability of pharmacies due to below-cost reimbursement. The “Federal Upper Limit”
refers to the maximum amount Medicaid will reimburse certain drugs
(because it is capped by the Centers
for Medicare and Medicaid Services).
Finally, although it is too early to
evaluate whether the new AMP system
(which was slated to go into effect
January 1, 2008, before a judicial injunction prevented its full implementation) negatively impacts access to
quality care for Medicaid beneficiaries,
the large presence of pharmacies
throughout the country suggests that
access to drugs will not suffer. It is
unlikely that lower reimbursement
rates will cause pharmacies to shut
down. The pharmacy industry should
take comfort in healthcare history
because the fears surrounding the new
AMP system mirror the fears (which

later turned out to be largely untrue)
that surrounded the implementation
of the ASP system. Just as physicians
changed their practice patterns under
the ASP system, it is likely that pharmacies, too, will alter their business
models to accommodate the shift in
reimbursement with the new AMP
system. In doing so, pharmacies will
continue making profits through government reimbursement rates of drugs
that accurately reflect pharmacy acquisition costs.
Ultimately, the ASP and revised AMP
systems will save taxpayer money that
has been spent on inaccurately priced
drugs and limit the damage of reduced
profits in the healthcare industry. The
foregoing analysis is even more significant when considering that this success foreshadows the likely adoption
of the new reimbursement systems by
private payers in the coming years.
See Page 13 for Citations
For a more in-depth paper on this
topic, please contact Marc Adler at
adlermar@shu.edu
or
madler@r2ss.com
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consultants to compare the efficiency
of New Jersey hospitals to national
and regional benchmarks, the results
of which the state could employ in
effectuating a new methodology for
Medicaid and Charity Care reimbursement. In response to the inefficiencies created by the misalignment of
hospital-physician financial incentives,
the Report urges the state to consider
a range of strategies, including physician reimbursement based upon severity-adjusted DRG or Relative Value
Units, physician rewards based upon
systemic cost savings, and the alignment of financial incentives and liability exposure.

Finally, the Commission Report raises
certain reform possibilities that it does
not actually recommend. It suggests
that economic credentialing might ameliorate the phenomenon of physicians
referring easy insured cases to ambulatory centers but difficult, risky or uninsured cases to hospitals, but then speculates that such a policy would result in
litigation. Similarly, the Report raises
the spectre of replacing the extant pricediscriminatory system of hospital pricing with a uniform all-payer system, but
ultimately demurs on the issue, lamenting that it is outside the scope of its
enabling executive order.

Conclusion
New Jersey’s brand new Commissioner of Health & Senior Services,
Heather Howard, who received the
Report on behalf of the Governor, is
apparently the primary person responsible for implementing its recommendations, but no new money has been
identified to support the Commission’s recommendations — not even
for the Distressed Hospital Program.
Her problems will be exacerbated if
anything resembling the current
budget proposal becomes law — it
proposes cuts of $3 billion in federal
funding to New Jersey hospitals over
the next five years.
See Page 13 for Citations
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Health Law Forum News
Valentine’s Day Blood Drive
Newark, NJ — February 14, 2008
The turnout was great, even for a chilly
day in February. Members of Health
Law Forum, along with the Public Interest Network and Environmental Law
Society, organized a successful drive
that touted the slogan “Have a Heart,
Donate Blood.”

In true law school fashion, a student reads
while donating.

Bandaged
snacks.

Students

enjoy

post-donation

Nurses and medical assistants from
New Jersey Blood Services skillfully
drew blood while members of the three
student groups cheerfully manned the
table, donated blood, and handed out
Valentine’s Day candy to students and
faculty. The day went smoothly with

no mishaps, as indicated by one
nurse’s comment on her gratitude
that “the fire alarm didn’t go off again
like last year.”
Of the 65 donors present, 57 were
able to give blood and help save lives
in New Jersey and around the country. The drive was a success due to
the dedication and enthusiasm of the
students at Seton Hall and the staff of
NJ Blood Services.

Rationalizing Health Care in New Jersey: A Discussion
Newark, NJ — March 11, 2008
The Seton Hall Law School Health Law
Forum and Seton Hall Health Law and
Policy Program recently hosted the
New Jersey Commissioner of Human
Services, Jennifer Velez.
Commissioner Velez spoke about the
findings and Recommendations in the
Final Report of the New Jersey Commission on Rationalizing Health Care Resources.
The event was attended by over 80 participants, including students, faculty,
and members of the community.

Other Health Law Forum
Events this year:
x

Speaker Nicole DiMaria,
Wolff
Sampson,
discussing STARK and
fraud and abuse laws

x

Screening of Sicko followed
by a discussion led by Frank
Pasquale, Professor of Law

x

Health law internship panel
with representatives from
pharma, government, hospitals and public interest

Health Law Advocates
Topics of Discussion:
x

Universal health care

x

Abigail Alliance for Better
Access to Experimental Drugs
v. Eschenbach

x

New rules for pharma and
patent protection

x

UMDNJ: Federal Monitors
and the emergence of nonprosecution agreements

x

Civil commitment of sex
offenders

x

SCHIP expansion and government-sponsored health
programs

W E ’ R E O N T H E
WEB!
L AW . S H U . E D U /
Commissioner Velez with members of the
Health Law Forum’s Executive Board
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those interested in health law.
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The Health Law Forum hosts speakers,
panel discussions, community service
projects, and networking events throughout each academic year.
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sub-group for students interested in
health policy, hosts monthly round-table
discussions about current topics in the
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Student Contributors
Christina Hage’s interest in the health care arena focuses primarily on issues regarding pharmaceutical and medical device marketing. Christina has interned at the New Jersey Attorney
General’s Office, the Honorable Judge Issenman’s Chambers, and Saint Peter's University
Hospital. This summer she will serve as a summer associate at Wolf Block located in Roseland, New Jersey.
Shelly Weizman’s interest in health policy lies in its intersection with a wide range of legal
and social issues, including access to health care and other benefits, mental illness and addiction, homelessness, physical disabilities, and special education. Her professional goal is to
promote systemic reform for underserved populations.
Prior to coming to Seton Hall, Sarah Geers worked as a Pharmaceutical Scientist at Merck in
Rahway, New Jersey. As part of her research career, she developed clinical trial and marketed drugs and investigated new formulation technologies, which led to an internship in the
Patent Department. This summer she will be returning to the Merck Patent Department.
Marc Adler has served as a legal extern at the University of Medicine and Dentistry of NJ,
and is currently employed part-time as an associate at R-Squared, a consulting firm that
works with a variety of healthcare and life sciences organizations. Marc has authored numerous legal papers, which are pending publication in the Bureau of National Affairs and the
Journal of Legal Medicine. He has also won first place in the national writing competition sponsored by the American College of Legal Medicine.
Nicole Ho worked as a research associate at Merck Research Labs and Bristol-Myers Squibb
prior to law school. Nicole received the Merck Patent Fellowship and will be working as an
intern at the patent office at Merck and Co., Inc. Nicole is a member of the Seton Hall
Health Law Forum and Health Law Advocates.
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